MedWatch

Analyst: Novo has a new blockbuster on their hands

If the combination drug IDegLira wins approval, Novo Nordisk could have a new global blockbuster on their hands, says analyst Frank H. Andersen. However, the rejection of Tresiba in the US has cut billions of its potential peak-sales.

Foto: Novo Nordisk/PR

According to analyst Frank H. Andersen, Jyske Bank, Novo Nordisk can add billions to its corporate accounts in the future if the combination product – which the group submitted a European registration application for last week – wins approval.

“It doesn’t come as a great surprise. It was expected that the company would submit an application for this product around this time. We estimate peak sales in 2020 of DKK 7.5 billion (USD 1.3 billion), which would make this product a global blockbuster,” he tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier